Biogen

Biogen is bolstering the company’s multiple sclerosis pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic MR-004, which is being assessed for the potential treatment of gait deficits in MS.

Roche warned that Russia’s attack on Ukraine is disrupting the development of a new generation of multiple sclerosis (MS) drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials.

The investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in clinical trials compared to Sanofi’s Aubagio as Novartis aims to refresh the Swiss drugmaker’ portfolio of medicines in neurological diseases.